

PATENT REQUEST: STANDARD PATENT/PATENT OF ADDITION

we, being the person(s) identified below as the Applicant, request the grant of a patent to the person identified below as the Nominated Person, for an invention described in the accompanying standard complete specification.

Full application details follow.

[71] Applicant: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) and INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Address: 51/53 RUE DU DOCTEUR BLANCHE - 75016 PARIS, FRANCE and 101 RUE DE TOLBIAC - 75654 PARIS, CEDEX 13, FRANCE, respectively

[70] Nominated Person: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) and INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Address: 51/53 RUE DU DOCTEUR BLANCHE - 75016 PARIS, FRANCE and 101 RUE DE TOLBIAC - 75654 PARIS, CEDEX 13, FRANCE, respectively

[54] Invention Title: PEPTIDES FOR INHIBITING PEPSIN RELEASE

[72] Names of actual inventors: MONIQUE DESCROIX-VAGNE, DANIELLE PANSU and THIERRY TARRADE

[74] Address for service in Australia: c/o WATERMARK PATENT & TRADEMARK ATTORNEYS, of 290 Burwood Road, Hawthorn, Victoria 3122, Australia.

Attorney Code: WM

BASIC CONVENTION APPLICATION(S) DETAILS


[31] Application Number	[33] Country	Country Code	[32] Date of Application
9405162.0	UNITED KINGDOM	GB	16 MARCH 1994

Basic Applicant(s): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) and INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Drawing number recommended to accompany the abstract

SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES
(S.C.R.A.S) and INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
(INSERM)

By our Patent Attorneys
WATERMARK PATENT & TRADEMARK ATTORNEYS


.....
Ian A. Scott
Registered Patent Attorney

5 June 1998.


AUSTRALIA

Patents Act 1990

NOTICE OF ENTITLEMENT

We, SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) and INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) of 51/53 rue du Docteur Blanche - 75016 Paris, France and 101 rue de Tolbiac - 75654 Paris Cedex 13, FRANCE, respectively being the applicants in respect of Application No. 14870/95 state the following:-

The persons nominated for the grant of the patent have entitlement from the actual inventors by assignment.




The persons nominated for the grant of the patent are the applicants of the basic application listed on the patent request form.



The basic application listed on the request form is the first application made in a Convention country in respect of the invention.



By our Patent Attorneys,
WATERMARK PATENT & TRADEMARK ATTORNEYS


.....
Ian A. Scott
Registered Patent Attorney

5 June 1998



(12) PATENT ABRIDGMENT (11) Document No. AU-B-14870/95
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 694476

(Modified Examination)


- (54) Title
PEPTIDES FOR INHIBITING PEPSIN RELEASE
- International Patent Classification(s)
 (51)⁶ **C07K 014/575 A61K 038/08 A61K 038/17**
- (21) Application No. : **14870/95** (22) Application Date : **14.03.95**
- (30) Priority Data
- (31) Number (32) Date (33) Country
9405162 16.03.94 GB UNITED KINGDOM
- (43) Publication Date : **28.09.95**
- (44) Publication Date of Accepted Application : **23.07.98**
- (71) Applicant(s)
**SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.);
 INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM)**
- (72) Inventor(s)
MONIQUE DESCROIX-VAGNE; DANIELLE PANSU; THIERRY TARRADE
- (74) Attorney or Agent
WATERMARK PATENT & TRADEMARK ATTORNEYS , Locked Bag 5, HAWTHORN VIC 3122
- (56) Prior Art Documents
**FR 2298334
 FR 2601020
 V/O 89/06241**

(57)

The invention relates to peptides able to inhibit the release of pepsin, to substitution derivatives and salts of such peptides and to pharmaceutical compositions containing these peptides. The peptides may be of use in the treatment of diseases related to the release of pepsin, and more particularly the treatment of ulcers or oesophagitis.

Claim

1. A peptide of the general formula I



in which:

A₁ represents the residue L-Thr or D-Thr; or one of the following sequences in which at least one amino acid residue may be of D configuration:

Val-Thr,

Pro-Val-Thr,

Arg-Pro-Val-Thr,

Glu-Arg-Pro-Val-Thr,

His-Glu-Arg-Pro-Val-Thr,

Gln-His-Glu-Arg-Pro-Val-Thr,

(11) AU-B-14870/95
(10) 694476

-2-

Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Pro-Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr or
Glu-Pro-Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr;

A₂ represents the sequence Lys-Pro-Gln-Ala in which at least one amino acid residue may be of D configuration;

A₃ represents a covalent bond or the sequence Gly-A₄-A₅ in which each of A₄ and A₅ independently represents a basic amino acid residue; and

X represents a hydroxy, amino or alkylamino group; with the proviso that the peptide contains at least one D-amino acid residue.

AUSTRALIA

Patents Act 1990

**ORIGINAL
COMPLETE SPECIFICATION
STANDARD PATENT**

Application Number:

Lodged:

Invention Title: PEPTIDES FOR INHIBITING PEPSIN RELEASE


The following statement is a full description of this invention, including the best method of performing it known to us :-

The invention relates to peptides able to inhibit the release of pepsin, to substitution derivatives and salts of such peptides and to pharmaceutical compositions containing these peptides. The peptides may be of use in the treatment of diseases related to the release of pepsin, and more particularly the treatment of ulcers or oesophagitis.

5 A new peptide has recently been isolated from pig intestines; this peptide, known as sorbin, has 153 natural amino acids (WO 89/06241). Sorbin and its C terminal peptide fragments (up to 40 amino acid residues) are able to provoke an increase in the process of absorption by the mucosa. We have unexpectedly found that the modification of these peptide fragments by the insertion of at least one D-amino acid residue confers another
10 biological activity on these modified peptide analogues: they inhibit the release of pepsin, a biological activity which unmodified peptides do not have.

This activity is particularly interesting in certain circumstances. Gastric digestion is the result of the action of enzymes, hydrochloric acid and pepsin. Pepsin is a protein; with gastrin, it is also one of the main constituents of the gastric juice. Its main physiological
15 role is the initiation of protein digestion. However, many studies have shown the significant role of pepsin in the formation of ulcers. Consequently, in certain circumstances it may be desirable to inhibit the release of pepsin at least in part.

The invention provides a peptide of the general formula I



20 in which:

A₁ represents the residue L-Thr or D-Thr; or one of the following sequences in which at least one amino acid residue may be of D configuration:

Val-Thr,



- Pro-Val-Thr,
Arg-Pro-Val-Thr,
Glu-Arg-Pro-Val-Thr,
His-Glu-Arg-Pro-Val-Thr,
5 Gln-His-Glu-Arg-Pro-Val-Thr,
Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
10 Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,
Pro-Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr or
Glu-Pro-Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr;

15 A₂ represents the sequence Lys-Pro-Gln-Ala in which at least one amino acid residue may be of D configuration;

A₃ represents a covalent bond or the sequence Gly-A₄-A₅ in which each of A₄ and A₅ independently represents a basic amino acid residue; and

X represents a hydroxy, amino or alkylamino group; with the proviso that the peptide contains at least one D-amino acid residue.

- 20 The invention also provides substitution derivatives of the peptides of the general formula I in which one or more of the amino acid residues is substituted by a protecting group or protecting groups conventionally employed in peptides intended for biological use; when there are two or more protecting groups, they need not be the same. Preferably, the protecting groups are selected from lower alkyl, such as methyl or t-butyl; phenyl; benzyl
25 or substituted benzyl such as trimethoxybenzyl; 2-chlorobenzoyloxycarbonyl; 9-fluorenylmethyloxycarbonyl (Fmoc); t-butoxycarbonyl (Boc); acetyl; sulphonyl; and phosphoryl groups.

The invention further provides peptides containing the amino acid sequence A₁-A₂-A₃, in which A₁, A₂ and A₃ are as defined above.

- 30 The invention yet further provides pharmaceutically acceptable salts of peptides as defined above. These salts may be obtained with organic acids such as acetic, lactic, palmoic, maleic, citric, malic, ascorbic, benzoic, salicylic, succinic, methylsulphonic and



toluenesulphonic acids; mineral acids such as hydrochloric, sulphuric or phosphoric acids; or polymeric acids such as tannic acid or carboxymethyl cellulose.

Each of A₄ and A₅, when present in peptides according to the invention, preferably independently represents a Lys, D-Lys, Arg or D-Arg residue.

- 5 As noted above, the peptides according to the invention contain one or more D-amino acid residues. When there is one, it is preferably the N terminal residue or the C terminal residue. When there are two, one is preferably the C terminal residue; the other may be located at any position, but is preferably the N-terminal residue. The preferred peptides are those in which A₂ represents Lys-Pro-Gln-D-Ala and A₃ represents a covalent bond.
- 10 Preferred substitution derivatives of the peptides include those in which Lys residues bear acetyl protecting groups.

Examples of the preferred peptides according to the invention are the following:

- Thr-Lys-Pro-Gln-D-Ala-NH₂,
Thr-Lys-Pro-Gln-D-Ala-Gly-Lys-Lys-NH₂,
15 Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH₂,
Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂,
Pro-D-Val-Thr-Lys-Pro-Gln-Ala-NH₂,
Pro-Val-Thr-Lys-Pro-Gln-Ala-Gly-Arg-D-Arg,
Pro-Val-Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH₂,
20 D-Pro-Val-Thr-Lys-Pro-Gln-Ala-NH₂,
His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂,
Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂,
Glu-Pro-Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂,
25 D-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂.
D-Pro-Val-Thr-Lys-Pro-Gln-Ala-Gly-D-Lys-Lys-NH₂,
Pro-D-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂ and
D-Pro-Val-Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH₂.

- 30 The peptides according to the invention may be prepared by any of the conventional peptide synthesis methods. For example, they may advantageously be prepared by solid phase synthesis carried out as follows: the formation of the peptide chain begins with the fixing of the C terminal amino acid of the chain via its carboxy group to a resin; the amino function is protected with a protecting group such as Boc. After fixing the C terminal

amino acid to the resin, its amine function is deprotected by washing the resin with an acid. In the case of protection with Boc, deprotection can take place by washing with trifluoroacetic acid. The second amino acid, the amine function of which is protected, is then coupled via its carboxy group to the deprotected amino function of the C terminal amino acid of the chain. This coupling preferably takes place in the presence of a coupling agent such as dicyclohexylcarbodiimide or diisopropylcarbodiimide. The peptide chain thus formed comprises two amino acids, the end amine function of which is protected. As before, this end amine function is deprotected and the fixing of the third amino acid can take place. The desired peptide chain is thus obtained by fixing the amino acids one after the other. After elimination of all the protecting groups, the peptide is detached from the resin.

The synthesis of a peptide of the invention, Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂, is described briefly below. Other peptides of the invention can be prepared by suitable modifications of this peptide synthesis.

15 The synthesis is carried out in the solid phase at ambient temperature. The method used comprises the following stages: deprotection, neutralisation and coupling. The resin used is of the cross-linked polystyrene type with 1% divinyl benzene (Merrifield resin). Boc-D-Ala is fixed to the Merrifield resin in the presence of caesium carbonate in toluene and dimethylformamide (DMF). The terminal amine function of the amino acids used is protected by the Boc group. These Boc groups are displaced by trifluoroacetic acid followed by several washings with dichloromethane and isopropanol. The amino groups are neutralised with triethylamine followed by several washings. The threonine and valine are transformed before coupling into an ester of hydroxybenzotriazole in the presence of diisopropylcarbodiimide (DIPCDI) ; for glutamine, the ester of hydroxybenzotriazole is formed directly in the reactor. The lysine and the two prolines are transformed into symmetrical anhydride before coupling. In all cases, coupling takes place in the presence of diisopropylethylamine. The side chain of the lysine is protected by an Fmoc grouping, whereas that of the threonine is not protected. On completion of the last coupling, the Fmoc grouping is displaced by piperidine in DMF before displacement of the Boc protecting group from the N terminal amine function of the proline. The peptide is obtained by cleavage of the resin after treatment in ammonia in a methanol/DMF mixture. The crude product thus obtained is then purified.

The invention additionally provides a pharmaceutical composition comprising a peptide of the general formula I as defined above, a substitution derivative of such a peptide as

defined above or a peptide including the amino acid sequence $A_1-A_2-A_3$ as defined above, in admixture with a pharmaceutically acceptable diluent or carrier.

Finally, the invention provides a method for the treatment of a patient suffering
 5 from gastric ulcers or cesophagitis, the method comprising administering to the patient an effective amount of a peptide of the general formula I as defined above, a substitution derivative of such a peptide as defined above or a peptide including the amino acid sequence $A_1-A_2-A_3$ as defined above, alone or in admixture with a pharmaceutically acceptable diluent or carrier.

10 The peptides of the invention can be administered by the oral, intravenous, parenteral, subcutaneous, intraperitoneal or intramuscular routes.

The pharmaceutical composition may take the form of a capsule, a tablet, a lyophilate or a liquid depending on the method of administration selected. The pharmaceutical composition may also take the form of a prolonged release
 15 formulation.

By the oral route, peptides according to the invention may be administered in man at a dose of 5 to 100 $\mu\text{g}/\text{kg}$ per day. By the intravenous or subcutaneous route, peptides according to the invention may be administered in man at a dose of 1 to 12 $\mu\text{g}/\text{kg}$ one to three times per day. In the animal, the preparations
 20 according to the invention are found in large quantities in the organism several days after one acute administration, and more particularly the peptide Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂ which is found in quantities greater than 10%.

Toxicity

The subacute toxicity was studied in the rat and the dog. Following
 25 administrations of doses up to 4000 $\mu\text{g}/\text{kg}/\text{d}$, no sign of toxicity and no signs



suggesting a mutagenic power were observed four weeks after administration. In man, a subcutaneous or intravenous injection at the dose of 200 $\mu\text{g}/\text{kg}$ 5 causes no biological, clinical or pathological anomaly.

Pharmacology

The therapeutical interest of the peptides of the invention has been established by the following experiment.

The intensity of the gastric response is measured by determining the volume of 10 gastric secretion induced.

Cats were operated on under general anaesthetic; the operation allowed the stomach to be divided into two parts: Heidenheim's pouch and the gastric fistula. These two pouches are diverted to the outside in order to recover the secretions of hydrochloric acid, pepsin and gastric juices, once the basal phase and then 15 after stimulation. These casts have chronic fistulas: they can therefore undergo a number of tests each week and be their own controls. The secretion of pepsin is stimulated by administration to the living animals of



pentagastrin (PG) and VIP (Vasoactive Intestinal Peptide) by perfusion for 2 hours at the rate of 2 and 4 $\mu\text{g}/\text{kg}/\text{h}$.

5 One hour after stimulation by pentagastrin and VIP, these peptides were added in perfusion at the dose of 100 pmol/kg/h. The volume of gastric juices was collected over the 30 minutes preceding perfusion until the end of perfusion. The quantity of pepsin in the gastric juice (as homogeneous as possible) was evaluated by a proteolytic spectrophotometric method.

10 The results obtained in 9 to 12 experiments are reported in the Tables below: the secretion of pepsin is expressed in mg/15 minutes, mean of 2 periods of 15 minutes per test during the basal secretion and mean of 6 periods of 15 minutes during the stimulated secretion.

Certain peptides of the invention with at least one D-amino acid residue are compared with their analogues in which all the amino acid residues are of L configuration.



TABLE 1

Comparison of the activity of a peptide of the invention P_{D_1} : Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂.

with that of its analogue

5 P_1 : Pro-Val-Thr-Lys-Pro-Gln-Ala-NH₂

	VIP + PG	VIP + PG + P_1	VIP + PG + P_{D_1}
Cat No 1	1.775	0.952	0.926
Cat No 2	1.316	1.367	1.711
Cat No 3	2.049	1.680	1.846
Cat No 1	1.852	2.993	2.082
Cat No 2	3.334	2.418	2.157
Cat No 3	4.010	5.392	3.932
Cat No 1	2.520	1.729	1.456
Cat No 2	2.409	2.403	1.516
Cat No 3	4.277	3.989	3.891
Cat No 1	1.750	-	-
Cat No 2	1.556	-	-
Cat No 3	4.442	-	-
Mean	2.607	2.547	2.169
Std Dev	0.323	0.468	0.351

"The numbers in the table refer to the amount of pepsin secreted in mg/15 min"

SECRET



TABLE 2

Activity of the peptides of the invention

PD₂ : D-Pro-Val-Thr-Lys-Pro-Gln-Ala-NH₂,

PD₃ : Pro-Val-Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH₂

5 PD₄ : D-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂

	VIP + PG	VIP + PG + PD ₂	VIP + PG + PD ₃	VIP + PG + PD ₄
Cat no 1	6.727	2.689	2,317	4,427
Cat no 2	4.773	2.007	1,860	2,999
Cat no 3	4.324	2.576	0,891	2,898
Cat no 4	2.458	2.076	1,725	3,780
Cat no 5	3.744	2.689	2,630	3,740
Cat no 6	3.276	1.143	2,217	3,147
Cat no 7	2.708	2.409	1,899	2,452
Cat no 8	3.991	3.172	4,321	3,996
Cat no 9	0.384	1.036	0,738	0,236
Cat no 10	5.184	3.164	3,811	3,362
Mean	3.757	2.296**	2.241**	3,104**
Std Dev	0.544	0.235	0,358	0,368

"The numbers in the table refer to the amount of pepsin secreted in mg/15 min"



TABLE 3
Activity of the peptides of the invention

- PD₅ : Pro-D-Val-Thr-Lys-Pro-Gln-Ala-NH₂,
PD₆ : Pro-D-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂
5 PD₇ : D-Pro-Val-Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH₂

	VIP + PG	VIP + PG + PD ₅	VIP + PG + PD ₆	VIP + PG + PD ₇
Cat No 1	6.727	4.263	2.480	2.163
Cat No 2	4.773	2.435	2.544	2.995
Cat No 3	4.324	1.317	2.589	1.441
Cat No 4	2.458	3.191	3.110	2.834
Cat No 5	3.744	2.727	4.142	1.236
Cat No 6	3.276	3.486	1.710	2.047
Cat No 7	2.708	2.634	2.370	2.544
Cat No 8	3.991	2.852	4.165	3.971
Cat No 9	0.384	1.132	1.693	1.520
Cat No 10	5.184	3.804	2.931	3.402
Mean	3.757	2.784	2.773	2.415
Std Dev	0.544	0.315	0.270	0.284

"The numbers in the table refer to the amount of pepsin secreted in mg/15 min"



TABLE 4

Activity of the peptides of the invention

PD₈ : His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂

PD₉ : Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂

5 PD₁₀ : Glu-Pro-Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂.

	VIP + PG	VIP + PG + PD ₈	VIP + PG + PD ₉	VIP + PG + PD ₁₀
Cat no 1	3.832	3.117	2.409	2.691
Cat no 2	1.826	2.730	1.440	1.764
Cat no 3	2.132	1.690	1.964	2.520
Cat no 4	3.891	1.725	2.259	2.410
Cat no 5	2.042	2.076	1.230	2.833
Cat no 6	3.250	1.358	1.580	2.877
Cat no 7	4.014	2.452	2.488	1.726
Cat no 8	4.280	2.689	2.426	2.015
Cat no 9	3.273	2.920	3.790	1.953
Mean	3.171	2.306*	2.176*	2.310*
Std Dev	0.313	0.206	0.254	0.151

"The numbers in the table refer to the amount of pepsin secreted in mg/15 min"



TABLE 5

Comparison of the activity of a peptide of the invention

PD₈: His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂

with that of its analogue

5 P₈ His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-Ala-NH₂

	VIP + PG	VIP + PG + P ₈	VIP + PG + PD ₈
Cat no 1	4.385	3.693	2.717
Cat no 2	4.460	4.915	4.630
Cat no 3	3.079	3.350	2.198
Cat no 4	3.333	2.442	1.746
Cat no 1	3.410	3.896	2.270
Cat no 2	2.510	2.432	2.245
Cat no 3	2.764	1.626	2.452
Cat no 4	2.191	1.925	2.247
Cat no 5	4.908	5.012	2.739
Mean	3.449	3.255	2.583*
Std Dev	0.314	0.412	0.274

"The numbers in the table refer to the amount of pepsin secreted in mg/15 min"



TABLE 6

Activity of the peptides of the invention

PD₁₁ : Thr-Lys-Pro-Gln-D-Ala-NH₂

PD₁₂ : Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH₂

5


	VIP + PG	VIP + PG + PD ₁₁	VIP + PG + PD ₁₂
Cat no 1	3.217	3.452	2.620
Cat no 2	3.772	3.114	1.925
Cat no 3	3.580	3.348	4.037
Cat no 4	2.166	2.181	1.896
Cat no 5	6.562	2.219	3.585
Cat no 6	2.290	1.638	2.192
Cat no 7	2.008	3.291	0.625
Cat no 8	2.034	2.076	1.339
Cat no 9	2.548	0.850	1.385
Mean	3.131	2.463	2.178*
Std Dev	0.484	0.299	0.364

"The numbers in the table refer to the amount of pepsin secreted in mg/15 min"



THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A peptide of the general formula I



in which:

5 A₁ represents the residue L-Thr or D-Thr; or one of the following sequences in which at least one amino acid residue may be of D configuration:

Val-Thr,

Pro-Val-Thr,

Arg-Pro-Val-Thr,

10 Glu-Arg-Pro-Val-Thr,

His-Glu-Arg-Pro-Val-Thr,

Gln-His-Glu-Arg-Pro-Val-Thr,

Leu-Gln-His-Glu-Arg-Pro-Val-Thr,

Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,

15 Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,

Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,

Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,

Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr,

Pro-Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr or

20 Glu-Pro-Gly-Lys-Ser-Ser-Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr;

A₂ represents the sequence Lys-Pro-Gln-Ala in which at least one amino acid residue may be of D configuration;

A₃ represents a covalent bond or the sequence Gly-A₄-A₅ in which each of A₄ and A₅ independently represents a basic amino acid residue; and

25 X represents a hydroxy, amino or alkylamino group; with the proviso that the peptide contains at least one D-amino acid residue.

2. A peptide containing the amino acid sequence A₁-A₂-A₃, in which A₁, A₂ and A₃ are as defined in claim 1, the peptide containing at least one D-amino acid residue.



3. A peptide according to claim 1 or 2 in which one or more of the amino acid residues is substituted by a protecting group or protecting groups, when there are two or more protecting groups, they need not be the same.
4. A peptide according to claim 3 containing at least one acetyl protected lysine residue.
5. A peptide according to claim 1 in the form of its pharmaceutically acceptable salt.
6. A peptide according to claim 1 in which the C-terminal amino acid residue is of D-configuration.
7. A peptide according to claim 1 in which the N-terminal amino acid residue is of D-configuration.
8. A peptide according to claim 1 in which A_2 represents Lys-Pro-Gln-D-Ala and A_3 represents a covalent bond.
9. A peptide of the formula Thr-Lys-Pro-Gln-D-Ala-NH₂.
10. A peptide of the formula Thr-Lys-Pro-Gln-D-Ala-Gly-Lys-Lys-NH₂.
11. A peptide of the formula Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH₂.
12. A peptide of the formula Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂.
13. A peptide of the formula Pro-D-Val-Thr-Lys-Pro-Gln-Ala-NH₂.
14. A peptide of the formula Pro-Val-Thr-Lys-Pro-Gln-Ala-Gly-Arg-D-Arg.
15. A peptide of the formula Pro-Val-Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH₂.



16. A peptide of the formula D-Pro-Val-Thr-Lys-Pro-Gln-Ala-NH₂.
17. A peptide of the formula His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂.
18. A peptide of the formula Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂.
19. A peptide of the formula Glu-Pro-Gly-Lys-Ser-Ser- Ile-Leu-Gln-His-Glu-Arg-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂.
20. A peptide of the formula D-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂.
21. A peptide of the formula D-Pro-Val-Thr-Lys-Pro-Gln-Ala-Gly-D-Lys-Lys-NH₂.
22. A peptide of the formula Pro-D-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂.
23. A peptide of the formula D-Pro-Val-Thr-(acetyl)Lys-Pro-Gln-D-Ala-NH₂.
24. A pharmaceutical composition comprising a peptide according to claim 1 in admixture with a pharmaceutically acceptable diluent or carrier.
25. Method for the treatment of a patient suffering from gastric ulcers or cesophagitis, the method comprising administering to the patient an effective amount of a peptide according to claim 1, alone or in admixture with a pharmaceutically acceptable diluent or carrier.

DATED this 10th day of February 1998

**SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS
SCIENTIFIQUES (SCRAS) and INSTITUT NATIONAL DE LA SANTE
ET DE LAR RECHERCHE MEDICALE (INSERM)**

WATERMARK PATENT & TRADEMARK ATTORNEYS
290 BURWOOD ROAD
HAWTHORN VICTORIA 3122
AUSTRALIA

IAS/JPF/ML DOC. 20 AU1487095.WPC



ABSTRACT

Peptides for Inhibiting Pepsin Release

Peptides derived from the C terminal sequence of sorbin, but containing at least one D-amino acid residue, inhibit pepsin release and are therefore likely to be useful in the treatment of ulcers or oesophagitis. Their salts and substitution derivatives are also claimed as a pharmaceutical compositions containing them. A method for the treatment of a patient suffering from gastric ulcers or oesophagitis comprising the administration of said peptides, is also claimed.

5
6
7
8
9

10
11
12

13
14

